# Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults

> **NCT04213105** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 144 (estimated)

## Conditions studied

- Healthy People

## Interventions

- **DRUG:** QL1206
- **DRUG:** Prolia®

## Key facts

- **NCT ID:** NCT04213105
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-10-31
- **Primary completion:** 2020-10-31
- **Final completion:** 2020-10-31
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2019-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04213105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04213105, "Comparing of the Pharmacokinetic, Safety and Pharmacodynamic of QL1206 and Prolia® in Healthy Adults". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04213105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*